Jennifer Panagoulias

In this interview, Jennifer discusses her experience working in the regulatory space, and shares some practical advice for academic labs preparing their first IND application for a gene therapy. 
 
Jennifer Panagoulias is the COO at AS2 Bio and the Head of Regulatory & Policy at Foundation for Angelman Syndrome Therapeutics (FAST). She is the regulatory lead for the SCGE project “A Non-viral CRISPR-mediated Genome Editing Delivery Platform As A Potential Therapy For Neurogenetic Diseases“.